Moderna (MRNA) and Merck (MRK) announce 5yr data for Intismeran in combination with Keytruda

The announcement of sustained improvement in recurrence-free survival (RFS) from the combination treatment of Intismeran and Keytruda is significant for both Moderna and Merck.

Newsquawk StaffPublished On the live feed at 3 more headlines followed before this page went public
Newsquawk headlinesUTC

Austria to sell EUR-denominated 10yr and 20yr debt via syndication

UK approves China's plans to construct 'mega embassy' in London

Moderna (MRNA) and Merck (MRK) announce 5yr data for Intismeran in combination with Keytruda

Deutsche Boerse (DB1 GY) is reportedly close to a EUR 5.3bln deal for Allfunds, via Bloomberg

Newsquawk Daily US Opening News - 20th January 2026

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
  • In this pre-planned analysis, adjuvant treatment with intismeran autogene in combination with Keytruda continued to demonstrate sustained and clinically meaningful improvement in the study's primary endpoint, recurrence-free survival, RFS, reducing the risk of recurrence or death by 49% compared to KEYTRUDA alone.
Context

It suggests a strong therapeutic benefit that could bolster market confidence in their product offerings, potentially influencing stock performance positively and prompting investor interest in the biotech sector.

Related headlines

The whole workspace, free to try.

Try it free